Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2Plasma cell 1Myeloid 1Classical hematology 1

Conditions

Lymphoma 2Hematologic Neoplasms 2Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia 1Bone Marrow Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 217fludarabine phosphate 120Rituximab 108Filgrastim 100Peripheral Blood Stem Cell Transplantation 86Etoposide 83fludarabine 80Busulfan 80Radiotherapy 76Tacrolimus 73Methotrexate 73Melphalan 71Mycophenolic Acid 70Cytarabine 65Antilymphocyte Serum 61Whole-Body Irradiation 56Cyclosporine 54Vincristine 49Prednisone 42Doxorubicin 41Methylprednisolone 34Granulocyte Colony-Stimulating Factor 34Dexamethasone 30Cord Blood Stem Cell Transplantation 29sargramostim 27Alemtuzumab 26Stem Cell Transplantation 24Carmustine 24Thiotepa 23thymoglobulin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × darinaparsin × Other hematologic neoplasm × Clear all
NCT00421213 2012-07-19

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Alaunos Therapeutics

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Bone Marrow Neoplasms, Hematologic Neoplasms

NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡